---
title: "UroGen buys IconOVir assets for 374,843 shares and a possible $15.0 million"
url: "https://aibio.space/news/urogen-buys-iconovir-assets-374-843-shares-possible-15-0-million/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-02-20"
section: "Financings"
tickers: "NASDAQ:URGN"
source: "https://www.sec.gov/Archives/edgar/data/1668243/000119312525030143/d897858d8k.htm"
summary: "The deal covers the product candidate ICVB-1042. A director's affiliates hold IconOVir notes that may entitle them to about 28.3% of the purchase price."
---

By the aibio.space news desk.

Sources

- [UroGen Pharma Ltd. 8-K (2025-02-20)](https://www.sec.gov/Archives/edgar/data/1668243/000119312525030143/d897858d8k.htm)

[URGN](https://aibio.space/companies/urogen-pharma/)

2025-02-20

# UroGen buys IconOVir assets for 374,843 shares and a possible $15.0 million payment

Tickers [URGN](https://aibio.space/companies/urogen-pharma/)

The deal covers the product candidate ICVB-1042. A director's affiliates hold IconOVir notes that may entitle them to about 28.3% of the purchase price.

## Key facts

- **Company**: UroGen Pharma Ltd. (NASDAQ: URGN)

- **News type**: Financings

- **Primary source**: [UroGen Pharma Ltd. 8-K (2025-02-20)](https://www.sec.gov/Archives/edgar/data/1668243/000119312525030143/d897858d8k.htm)

*Stock prices on an electronic board. CC0, via rawpixel. The picture shows the field, not the companies named.*

UroGen Pharma Ltd. (Nasdaq: [URGN](https://aibio.space/companies/urogen-pharma/)) and its subsidiary UroGen Pharma, Inc. signed an Asset Purchase Agreement with IconOVir Bio, Inc. on February 14, 2025. UroGen acquired certain IconOVir assets, including the product candidate ICVB-1042, related contracts, intellectual property, regulatory filings and data. It also assumed certain liabilities.

On the closing date, UroGen issued 374,843 ordinary shares to IconOVir. That number reflects a purchase price of $4.0 million divided by the volume-weighted average closing price over the 30 trading days before closing. UroGen also agreed to pay a one-time $15.0 million in cash if cumulative worldwide net sales of ICVB-1042 products reach a set milestone, and a low, single-digit percentage royalty on annual worldwide net sales of each product.

UroGen agreed to use commercially reasonable efforts to develop and commercialize one ICVB product until the earlier of the 10th anniversary of closing and the first commercial sale of any such product. It granted IconOVir piggyback registration rights on the shares.

The filing says entities affiliated with Arie Belldegrun, M.D., the chair of UroGen's board, hold promissory notes of IconOVir that may entitle them to approximately 28.3% of the purchase price. The shares were issued under Section 4(a)(2) of the Securities Act of 1933.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

URGN

UroGen Pharma Ltd.

NASDAQ · United States

Open the starter desk

## More in Financings

Financings

### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/)

Oct 29, 2026

Financings

### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/)

Oct 29, 2026

Financings

### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/)

Oct 29, 2026

---
Source page: https://aibio.space/news/urogen-buys-iconovir-assets-374-843-shares-possible-15-0-million/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "UroGen buys IconOVir assets for 374,843 shares and a possible $15.0 million", 2025-02-20, https://aibio.space/news/urogen-buys-iconovir-assets-374-843-shares-possible-15-0-million/